Since inhibition of the glycogen synthase kinase 3 has also been shown to suppress PD-1 expression and interfere with the PD-1/PD-L1 axis, Allen et al. constructed the lipid bilayer-coated MSNs loaded with the GSK3 inhibitor AZD1080 for the immunotherapy of colorectal, pancreatic, and lung cancers [419]. This evidence concerns the gene PDCD1 and lung carcinoma.